BREAKING NEWS: Anthos Therapeutics’ Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab, Demonstrated a 67% Greater Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding 
Compared to Rivaroxaban in Patients with Atrial Fibrillation

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.

OUR SCIENCE

Our most advanced program is abelacimab, an investigational monoclonal antibody that achieves profound suppression of the novel antithrombotic target Factor XI through dual activity against both Factor XI itself and its activated form, Factor XIa. Abelacimab represents a promising next-generation anticoagulant with the potential to provide ‘hemostasis-sparing anticoagulation’: vital protection from arterial and venous thromboembolic events with a reduced risk of clinically significant bleeding.

A MAJOR UNMET NEED

Due to prevailing fears of bleeding, effective prevention of thromboembolic events through optimal anticoagulation remains a real-world unmet need.

ABOUT ABELACIMAB

Abelacimab, with its novel dual activity against Factor XI and XIa, has the potential to turn our vision of hemostasis-sparing anticoagulation into reality.

NEWS

Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

NEWS PROVIDED BY Anthos Therapeutics → November 12, 2023 08:15 ET Secondary Endpoints Also Showed a Highly Significant 74% Reduction in Major Bleeding and a 93% Reduction in Gastrointestinal (GI) Bleeding with Abelacimab These Results Triggered the Data Monitoring...